FLAG 003
Alternative Names: FLAG-003Latest Information Update: 19 Jul 2024
At a glance
- Originator Duquesne University
- Developer FLAG Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diffuse intrinsic pontine glioma; Glioblastoma
Most Recent Events
- 16 Jul 2024 Preclinical trials in Diffuse intrinsic pontine glioma in USA (PO)
- 16 Jul 2024 FLAG Therapeutics announces intention to submit IND application to US FDA for Diffuse intrinsic pontine glioma in the fourth quarter of 2024
- 16 Jul 2024 Pharmacodynamics data from a preclinical trial in Diffuse intrinsic pontine glioma released by FLAG Therapeutics